parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.48 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including oligodendrocytes; strongest in esophageal apical cells	0.75
chemistry Open Targets	a small-molecule pocket	0.60
trials ClinicalTrials.gov	17 Parkinson's trials, 2 stopped	0.91
literature PubMed	187 Parkinson's papers of 22,219	0.31
pathways Reactome	4 pathways; mostly other	0.30

No case: the score is under the bar. Receipt 0273

receipt 0280: SCD in dopamine neurons, braak

power: full sample +0.06 (p 0.807, n 18), 95% CI -0.42 to +0.51. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.00 (p 0.990, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.13 (p 0.615, n 18). could be the mix.
skeptic: leave-one-out range -0.05 to +0.19, sign flips 4; without severely affected donors +0.06 (p 0.807, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for SCD in dopamine neurons.

case closed: nothing better to follow up.

receipt 0279: SCD in oligodendrocytes, braak

power: full sample +0.15 (p 0.549, n 18), 95% CI -0.34 to +0.58. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.10 (p 0.690, n 18). does not hold up.
composition: oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: +0.16 (p 0.521, n 18). could be the mix.
skeptic: leave-one-out range +0.05 to +0.30, sign flips 0; without severely affected donors +0.15 (p 0.549, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for SCD in oligodendrocytes.

case closed: nothing better to follow up.

loading the receipts